PriceTargets.com logo

Eyepoint Pharmaceuticals - EYPT Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $25.70
  • Forecasted Upside: 602.19%
  • Number of Analysts: 11
  • Breakdown:
  • 1 Sell Ratings
  • 6 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$3.66 As of 09/15/2026 05:00 PM ET
▼ -0.59 (-13.88%)

This chart shows the closing price for EYPT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Eyepoint Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for EYPT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for EYPT

Analyst Price Target is $25.70
▲ +602.19% Upside Potential
This price target is based on 11 analysts offering 12 month price targets for Eyepoint Pharmaceuticals in the last 3 months. The average price target is $25.70, with a high forecast of $68.00 and a low forecast of $4.00. The average price target represents a 602.19% upside from the last price of $3.66.

This chart shows the closing price for EYPT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 11 investment analysts is to hold stock in Eyepoint Pharmaceuticals. This rating changed within the last month from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/24/2025
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/22/2025
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/20/2025
  • 2 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
12/19/2025
  • 2 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
3/19/2026
  • 2 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
6/17/2026
  • 1 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
8/16/2026
  • 0 strong buy ratings
  • 4 buy ratings
  • 6 hold ratings
  • 1 sell ratings
Ratings as of
9/15/2026

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 6 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
9/2/2026TD CowenDowngradeBuy ➝ Hold$20.00 ➝ $4.00
9/1/2026Weiss RatingsUpgradeSell (E+) ➝ Sell (D-)
8/18/2026CitigroupLower TargetBuy ➝ Buy$17.00
8/18/2026Chardan CapitalDowngradeBuy ➝ Neutral$5.00
8/18/2026Royal Bank Of CanadaReiterated RatingOutperform ➝ Sector Perform$5.00
8/18/2026HC WainwrightReiterated RatingBuy ➝ Neutral
8/17/2026Weiss RatingsDowngradeSell (D-) ➝ Sell (E+)
8/17/2026Royal Bank Of CanadaDowngradeOutperform ➝ Sector Perform$5.00
8/17/2026Jefferies Financial GroupLower TargetBuy ➝ Buy$8.00
8/17/2026JPMorgan Chase & Co.Reiterated RatingOverweight ➝ Neutral
8/17/2026Cantor FitzgeraldDowngradeOverweight ➝ Neutral
8/17/2026Chardan CapitalReiterated RatingBuy ➝ Neutral$65.00 ➝ $5.00
8/7/2026Chardan CapitalReiterated RatingBuy ➝ Buy$65.00
8/6/2026Cantor FitzgeraldBoost TargetOverweight ➝ Overweight$47.00 ➝ $55.00
8/6/2026HC WainwrightLower TargetBuy ➝ Buy$30.00 ➝ $27.00
7/17/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
7/16/2026Stifel NicolausInitiated CoverageBuy$40.00
7/8/2026Cantor FitzgeraldInitiated CoverageOverweight$47.00
7/1/2026Chardan CapitalBoost TargetBuy ➝ Buy$29.00 ➝ $65.00
6/24/2026GuggenheimReiterated RatingBuy ➝ Buy$68.00
5/7/2026Royal Bank Of CanadaLower TargetOutperform ➝ Outperform$39.00 ➝ $37.00
4/21/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
3/9/2026CitigroupBoost TargetBuy ➝ Buy$31.00 ➝ $35.00
3/5/2026HC WainwrightBoost TargetBuy ➝ Buy$23.00 ➝ $30.00
3/4/2026Chardan CapitalBoost TargetBuy ➝ Buy$27.00 ➝ $29.00
1/22/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
12/19/2025TD CowenUpgradeStrong-Buy
11/25/2025Cantor FitzgeraldUpgradeStrong-Buy
11/6/2025Royal Bank Of CanadaBoost TargetOutperform ➝ Outperform$28.00 ➝ $39.00
10/20/2025MizuhoSet Target$28.00
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
8/7/2025Chardan CapitalReiterated RatingBuy ➝ Buy$27.00
8/6/2025HC WainwrightBoost TargetBuy ➝ Buy$22.00 ➝ $23.00
6/17/2025Royal Bank Of CanadaInitiated CoverageOutperform$28.00
5/29/2025HC WainwrightReiterated RatingBuy ➝ Buy$22.00
5/16/2025MizuhoLower TargetOutperform ➝ Outperform$30.00 ➝ $26.00
5/8/2025Chardan CapitalLower TargetBuy ➝ Buy$33.00 ➝ $27.00
3/6/2025Chardan CapitalReiterated RatingBuy ➝ Buy$33.00 ➝ $33.00
3/6/2025HC WainwrightReiterated RatingBuy ➝ Buy$22.00 ➝ $22.00
2/6/2025Chardan CapitalReiterated RatingBuy ➝ Buy$33.00 ➝ $33.00
1/7/2025CitigroupInitiated CoverageBuy$33.00
12/5/2024HC WainwrightReiterated RatingBuy ➝ Buy$22.00 ➝ $22.00
11/11/2024HC WainwrightLower TargetBuy ➝ Buy$30.00 ➝ $22.00
11/11/2024Robert W. BairdLower TargetOutperform ➝ Outperform$38.00 ➝ $33.00
11/8/2024Chardan CapitalBoost TargetBuy ➝ Buy$28.00 ➝ $33.00
10/29/2024Chardan CapitalReiterated RatingBuy ➝ Buy$28.00 ➝ $28.00
10/25/2024HC WainwrightReiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
10/16/2024ScotiabankInitiated CoverageSector Outperform$18.00
8/28/2024Jefferies Financial GroupInitiated CoverageBuy$15.00
8/13/2024JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$32.00 ➝ $29.00
6/28/2024Chardan CapitalReiterated RatingBuy ➝ Buy$28.00 ➝ $28.00
6/27/2024HC WainwrightReiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
6/20/2024Cantor FitzgeraldReiterated RatingOverweight
6/4/2024JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$35.00 ➝ $32.00
5/13/2024HC WainwrightLower TargetBuy ➝ Buy$33.00 ➝ $30.00
5/8/2024Robert W. BairdLower TargetOutperform ➝ Outperform$46.00 ➝ $38.00
5/7/2024Chardan CapitalLower TargetBuy ➝ Buy$39.00 ➝ $28.00
5/7/2024MizuhoLower TargetBuy ➝ Buy$39.00 ➝ $30.00
2/16/2024Capital One FinancialReiterated RatingOverweight
2/16/2024MizuhoBoost TargetBuy ➝ Buy$30.00 ➝ $39.00
1/22/2024JPMorgan Chase & Co.Initiated CoverageOverweight$35.00
1/16/2024HC WainwrightLower TargetBuy ➝ Buy$35.00 ➝ $33.00
12/11/2023Capital One FinancialInitiated CoverageOverweight$44.00
12/7/2023MizuhoBoost TargetBuy ➝ Buy$20.00 ➝ $30.00
12/5/2023HC WainwrightBoost TargetBuy ➝ Buy$25.00 ➝ $35.00
11/2/2023HC WainwrightLower TargetBuy ➝ Buy$27.00 ➝ $25.00
11/2/2023MizuhoInitiated CoverageBuy$20.00
9/14/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$31.00
9/12/2023HC WainwrightReiterated RatingBuy ➝ Buy$27.00
8/31/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$31.00
8/3/2023Chardan CapitalReiterated RatingBuy ➝ Buy$22.00
8/3/2023HC WainwrightReiterated RatingBuy ➝ Buy$27.00
7/28/2023HC WainwrightReiterated RatingBuy ➝ Buy$27.00
5/19/2023HC WainwrightBoost Target$25.00 ➝ $27.00
5/18/2023Chardan CapitalBoost Target$21.00 ➝ $22.00
4/20/2023Robert W. BairdInitiated CoverageOutperform$33.00
3/27/2023HC WainwrightReiterated RatingBuy$25.00
3/3/2023Chardan CapitalReiterated RatingBuy$21.00
2/28/2023HC WainwrightReiterated RatingBuy$25.00
11/11/2022GuggenheimLower TargetBuy$60.00 ➝ $52.00
8/4/2022HC WainwrightBoost Target$24.00 ➝ $25.00
8/2/2022HC WainwrightReiterated RatingBuy$24.00
7/7/2022Chardan CapitalInitiated CoverageBuy$21.00
3/4/2022Cantor FitzgeraldReiterated RatingOverweight
3/4/2022HC WainwrightReiterated RatingBuy$24.00
11/15/2021TD CowenBoost TargetOutperform$25.00 ➝ $35.00
11/15/2021HC WainwrightReiterated RatingBuy$15.00 ➝ $24.00
10/13/2021HC WainwrightReiterated RatingBuy$15.00
(Data available from 9/16/2021 forward)

News Sentiment Rating

0.14 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/18/2026
  • 2 very positive mentions
  • 14 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/20/2026
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/19/2026
  • 1 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/19/2026
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/18/2026
  • 0 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
7/18/2026
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/17/2026
  • 7 very positive mentions
  • 38 positive mentions
  • 9 negative mentions
  • 1 very negative mentions
Mentions as of
9/16/2026

Current Sentiment

  • 7 very positive mentions
  • 38 positive mentions
  • 9 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Eyepoint Pharmaceuticals logo
EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.
Read More

Today's Range

Now: $3.66
Low: $3.64
High: $4.27

50 Day Range

MA: $9.43
Low: $3.66
High: $14.84

52 Week Range

Now: $3.66
Low: $3.63
High: $19.11

Volume

3,887,253 shs

Average Volume

4,670,639 shs

Market Capitalization

$315.53 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.63

Frequently Asked Questions

What sell-side analysts currently cover shares of Eyepoint Pharmaceuticals?

The following Wall Street analysts have issued reports on Eyepoint Pharmaceuticals in the last year: Cantor Fitzgerald, Chardan Capital, Citigroup Inc., Guggenheim, HC Wainwright, Jefferies Financial Group Inc., JPMorgan Chase & Co., Mizuho, Royal Bank Of Canada, Stifel Nicolaus, TD Cowen, Wall Street Zen, and Weiss Ratings.
View the latest analyst ratings for EYPT.

What is the current price target for Eyepoint Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Eyepoint Pharmaceuticals in the last year. Their average twelve-month price target is $25.70, suggesting a possible upside of 602.2%. Guggenheim has the highest price target set, predicting EYPT will reach $68.00 in the next twelve months. TD Cowen has the lowest price target set, forecasting a price of $4.00 for Eyepoint Pharmaceuticals in the next year.
View the latest price targets for EYPT.

What is the current consensus analyst rating for Eyepoint Pharmaceuticals?

Eyepoint Pharmaceuticals currently has 1 sell rating, 6 hold ratings and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in EYPT, but not buy more shares or sell existing shares.
View the latest ratings for EYPT.

What other companies compete with Eyepoint Pharmaceuticals?

Other companies that are similar to Eyepoint Pharmaceuticals include Harrow, Alto Neuroscience, Calliditas Therapeutics AB (publ), Cronos Group and Cybin. Learn More about companies similar to Eyepoint Pharmaceuticals.

How do I contact Eyepoint Pharmaceuticals' investor relations team?

Eyepoint Pharmaceuticals' physical mailing address is 480 Pleasant Street, Suite C400, Watertown, MA, 02472. The company's listed phone number is (617) 926-5000 and its investor relations email address is [email protected]. The official website for Eyepoint Pharmaceuticals is www.eyepoint.bio. Learn More about contacing Eyepoint Pharmaceuticals investor relations.